Abstract | BACKGROUND: OBJECTIVE: We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate. METHODS: All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed. RESULTS: Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur. LIMITATIONS: The follow-up period was short, and there was no histologic confirmation of the initial diagnosis. CONCLUSION: IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.
|
Authors | Nicolas Aubut, Jimmy Alain, Joël Claveau |
Journal | Journal of cutaneous medicine and surgery
(J Cutan Med Surg)
2012 May-Jun
Vol. 16
Issue 3
Pg. 212-7
ISSN: 1203-4754 [Print] United States |
PMID | 22713449
(Publication Type: Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Methotrexate
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic
(administration & dosage, therapeutic use)
- Female
- Humans
- Injections, Intralesional
- Male
- Methotrexate
(administration & dosage, therapeutic use)
- Middle Aged
- Retrospective Studies
- Treatment Outcome
|